An investigation on behalf of investors of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) shares over potential securities laws violations by Xeris Pharmaceuticals, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) concerning whether a series of statements by Xeris Pharmaceuticals, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Chicago, IL based Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.

On or around June 20, 2018, Xeris conducted its initial public offering ("IPO"), selling 5,700,000 shares of common stock priced at $15.00 per share.

On March 9, 2021, Xeris Pharmaceuticals, Inc announced its fourth quarter and full year 2020 results. Xeris Pharmaceuticals, Inc. reported that its annual Total Revneue rose from $2.72 million in 2019 to $20.15 million in 2020, and that its Net Loss declined from $125.58 million in 2019 to $91.13 million in 2020. However, Xeris Pharmaceuticals, Inc reported fourth quarter GAAP earnings per share of $0.41, missing consensus estimates by $0.01, and revenue of $7.09 million, missing consensus estimates by $1.82 million.

Shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) declined to $3.98 per share on March 9, 2021.